UPDATED: MAR 22, 2017
The Next Generation of CBD Therapy with the Integration of Precision Medicine
Houston, Texas, March 22, 2017 (Newswire.com) – Cannliv, LLC (Cannliv) announces the formation of a contractual joint venture with Vyripharm Biopharmaceuticals, (Vyripharm) to provide medical cannabis to support Vyripharm’s research and development program dedicated to the treatment of epilepsy, once the State of Texas Compassionate Use Act (CUP) and Compassionate Use Registry of Texas (CURT) state initiative rolls out in 2017. In addition to epilepsy, Vyripharm’s research and development program is focused on cancers, PTSD and general cognitive disorders at medical facilities across Texas.
This design of the joint venture will be to produce medical cannabis for the healthcare industry that is specific to each unique person and condition through diagnostic molecular imaging of the patient and developing a molecular profile of the plant (agriculture profile). By integrating Vyripharm’s personalized platforms, this innovative approach will require the patient to undergo imaging scans as the patient is being treated to hopefully follow the efficacy of the drug during and after treatment. If the imaging procedure performed while the patient is undergoing therapy reveals that the patient is not responding to the treatment, the attending physician can use this critical information to determine if the therapy should be discontinued and a different therapy selected for the patient.
“With our partnerships in the U.S. and International partners, Cannliv facilitates proven strains of Low Level THC Cannabis and brings these products to the medical industry in research, human trials, and patient treatment, resulting in integrated personalized medicine.”
JOHN DAVID CARRASCO, PRESIDENT & CEO
This partnership continues Cannliv’s mission to produce medical grade CBD products through the use of Vyripharm’s patented platforms for medical cannabis product certification and medical cannabis research and development. Through controlled testing of medical cannabis products at a Vyripharm Cannabis Processing Center, or CPC, scientists can perform cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, liquid testing, and pathogen testing. This comprehensive testing platform should provide the standard for the medical cannabis industry in terms of quality control, quality assurance and patient safety.
Vyripharm will conduct its research and development using Cannliv’s medical cannabinoid products with their partnering medical institutions; UTMD Anderson, UTMB, Baylor College of Medicine and the VA Texas Healthcare System (in Houston,TX). The first of which occurred in August 2016 at UTMD Anderson.
Vyripharm President, Jerry Bryant, had this to say about the partnership, “For decades, chemotherapy and external radiation have remained an integral part of cancer therapy planning even in light of the adverse collateral effects of such therapies, however, if we can integrate medical cannabinoids with these treatments, we may be able to reduce the side effects and provide a better quality of life for cancer patients and their families. We believe cannabinoids will play a vital future role in the physician’s treatment plan addressing cancer and other types of disease disorders.”
Cannliv President & CEO, John David Carrasco stated, “During the last year, our efforts to understand the emerging cannabinoid markets has poised Cannliv to offer a comprehensive solution to the State of Texas for medical cannabis. With our partnerships in the U.S. and International partners, Cannliv facilitates proven strains of Low Level THC Cannabis and brings these products to the medical industry in research, human trials, and patient treatment, resulting in integrated personalized medicine.”
Vyripharm is focusing on theranostic medicine combining diagnostic molecular imaging with target specific therapy to provide a greater degree of precision in addressing the patient’s medical condition on a personal level. Healthcare providers and patients will be able to identify specific medical cannabis strains that react best to specific conditions, resulting in better treatment outcomes.
Cannliv’s first group of dispensaries will be located in Houston and Dallas, with additional locations across the state once qualified and Cannliv is awarded license. Their complete CANNLIVE 1.0 Solution will be used to manage our Seed to Sale internal system for inventory tracking, accounting and registry integration as defined by the State of Texas.
ABOUT CANNLIV, LLC
Cannliv is a Texas based biopharmaceutical manufacturer with its sole purpose to produce a natural, clean and user-friendly Cannabinoid products made with the purist ingredients for a truly consistent and reliable source of CBD. Cannliv will be applying for the Compassionate Use Program licensing this month and will be announcing key partners resulting in proven treatment solutions for Texas.
ABOUT VYRIPHARM BIOPHARMACEUTICALS
Vyripharm is a biopharmaceutical firm focused on natural products, regulatory testing, pharmaceutical drug development of imaging agents, and drug delivery systems. The aim of Vyripharm is to improve clinical management through diagnosis and treatment with botanicals, synthetic pharmaceuticals, and drug delivery systems.
Press and Investor Inquiries:
Toll Free: 844-923-7877
Source: Cannliv, LLC